Sanofi will now work with provincial, territorial and federal drug programs to support access to the treatment for eligible patients through public drug plans
Exports & formulations power growth
The approvals cover Vancomycin and Fluorouracil in Kazakhstan, Fulvestrant in Peru, Methotrexate in Kuwait, and Meropenem in Argentina
Sharpens focus on healthcare innovation and growth in India
Both funds will target companies spanning biopharmaceuticals, medical devices, diagnostics and technology-enabled healthcare services
Industry leaders will discuss AI adoption, cybersecurity, ERP modernisation and regulatory compliance as technology takes centre stage in pharma’s next phase of growth
Lonza has completed its shift to a pure-play CDMO following its exit from the Capsules & Health Ingredients business and further divestments
Pfizer will take responsibility for clinical development, manufacturing, regulatory affairs and commercialisation after the collaboration term
The study will evaluate whether AI-assisted endoscopy can help clinicians detect upper gastrointestinal malignancies earlier and more effectively
The funding will support the advancement of Soufflé’s three lead programs into clinical studies
The partnership aims to accelerate the development of innovative treatments by using artificial intelligence to engineer proteins
India-specific pricing to improve affordability & accessibility for children with growth disorders
In its first phase, the facility will manufacture oral solid dosage forms for the Sri Lankan market
The collaboration marks a push to develop a differentiated approach to obesity treatment by targeting fat tissue directly
Sun Pharma Board approves Rs. 10,000 crore NCD issuance
The aim is to address the unique health challenges faced by Armed Forces personnel and civilians living in the Himalayan belt
The expansion adds local production of Aptar’s pressurized metered dose inhaler (pMDI) valves, breath-actuated systems and multi dose nasal spray systems
The Armenian Ministry of Health granted separate marketing authorizations for the two medicines
Ono will secure exclusive rights to develop and commercialize Biohaven’s MoDE pan-IgG degrader portfolio in Japan, South Korea, Taiwan and the Association of Southeast Asian Nations (ASEAN) region
Subscribe To Our Newsletter & Stay Updated
